8-K: Apogee Therapeutics Announces Positive Phase 2b Results for Zumilimabart

Apogee Therapeutics reported positive 16-week induction dose optimization results from its Phase 2 APEX trial for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints.

Summary

• Apogee Therapeutics announced positive 16-week results from Part B of its Phase 2 APEX clinical trial for zumilokibart (APG777), an anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD).
• The trial met its primary endpoint of EASI-75 (Eczema Area and Severity Index 75% reduction) with the mid-dose achieving 65.9% response compared to 23.4% for placebo (p<0.001).
• Key secondary endpoints were also met, including IGA 0/1 response (46.0% vs. 10.9% for placebo, p<0.001) and EASI-90 response (47.4% vs. 9.3% for placebo, p<0.001).
• Zumilokibart was well-tolerated, with a safety profile consistent with its class. The most common adverse events were nasopharyngitis, headache, and noninfective conjunctivitis.
• Apogee plans to advance the mid-dose of zumilokibart into Phase 3 trials for moderate-to-severe AD in the second half of 2026, pending regulatory interactions.
• The company also shared plans for Phase 3 trials in asthma and eosinophilic esophagitis (EoE), supporting the 'pipeline-in-a-product' potential of zumilokibart.
• A strategic financing collaboration with Blackstone Life Sciences was announced, expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong clinical efficacy demonstrated, meeting all key endpoints, a favorable safety profile, and significant progress towards Phase 3 trials and commercialization, bolstered by substantial financing.

Positives

• The Phase 2 APEX Part B trial met its primary endpoint (EASI-75) with statistically significant results across all tested doses of zumilokibart compared to placebo.
• The mid-dose of zumilokibart demonstrated strong efficacy, achieving 65.9% EASI-75 response, and also met key secondary endpoints.
• Zumilokibart showed a favorable safety profile, generally consistent with other agents in its class, with a pooled conjunctivitis rate of 10.6% for the planned Phase 3 dose.
• The drug demonstrated rapid onset of action, with significant improvements in lesions and itch observed as early as Week 1.
• The company plans to initiate Phase 3 trials for AD in the second half of 2026, indicating progress towards potential commercialization.
• Strategic financing with Blackstone Life Sciences is expected to fund development through commercialization, reducing the need for future equity financing.
• Plans for Phase 3 trials in asthma and EoE highlight the broad potential of zumilokibart across multiple indications.

Negatives

• While generally well-tolerated, conjunctivitis was reported in 10.6% of patients on the planned Phase 3 dose, with higher rates in higher dose arms (15.1% low dose, 20.7% high dose).
• The filing does not provide specific financial metrics for the current reporting period, focusing instead on clinical trial results.

Risks

• Actual results of clinical trials may differ from preclinical study results.
• The timing or likelihood of regulatory filings and approvals remains uncertain.
• Global macroeconomic conditions and related volatility could impact the company.
• The company's ability to continue as a going concern is subject to future funding and successful product development and commercialization.
• The unpredictable relationship between preclinical and clinical study results, and the applicability of clinical study results to actual outcomes, pose inherent risks.

Future Outlook

Apogee plans to initiate Phase 3 trials for zumilokibart in moderate-to-severe atopic dermatitis in the second half of 2026, with a potential launch anticipated in 2029. The company also plans to initiate Phase 2b trials in asthma in the first half of 2027 and Phase 2a trials in eosinophilic esophagitis in the second half of 2026. The company expects various program readouts and milestones through 2028, including Phase 3 data readouts in 2028.

Management Comments

• "We are thrilled by the strength and consistency that zumilokibart demonstrated across all endpoints from today's APEX Part B induction results, which we believe could set a new standard of care for patients."
• "Today's results help clear our path to advance zumilokibart into the Phase 3 trials planned for the second half of this year and we look forward to engaging with regulatory agencies."
• "Zumilokibart has the potential to move the bar on disease control and dosing based on both today's data as well as the robust APEX Part A maintenance results that showed continued improvement in efficacy over 52 weeks with every 3- and 6- month dosing."
• "Beyond AD, we are excited to develop zumilokibart's pipeline-in-a-product potential and plan to commence Phase 2 studies in EoE in the second half of 2026 and asthma in the first half of 2027."
• "The APEX Part B results align extremely well with these patient-centric goals, particularly the achievement of very low disease activity, with simultaneous robust improvement in lesion and itch benefit in more than one fifth of mid-dose patients, which are results not seen with any biologic to date."
• "Together with Part A data demonstrating that zumilokibart can be dosed every 3 to 6 months in maintenance with continuous and even enhanced efficacy, we are seeing a strong clinical profile that offers what dermatologists are looking for in clinical practice for our patients."

Industry Context

StockSavvy.ai notes that Apogee Therapeutics' positive Phase 2 results for zumilokibart in atopic dermatitis place it in a competitive landscape with other IL-13 inhibitors and JAK inhibitors. The company's focus on extended half-life and less frequent dosing aligns with a key unmet need in the large and growing inflammatory and immunology market, particularly for atopic dermatitis, which is projected to be a significant market.

Comparison to Industry Standards

• The EASI-75 response rate of 65.9% for the mid-dose of zumilokibart at Week 16 is competitive with other approved therapies for moderate-to-severe atopic dermatitis. For example, Dupixent (dupilumab) has shown EASI-75 response rates in the range of 49.5% to 65.9% in its Phase 3 trials (SOLO-1&2, 300mg Q2W).
• The IGA 0/1 response rate of 46.0% for zumilokibart is also comparable to other biologics. Dupixent has shown IGA 0/1 response rates around 34.6% to 46.0% in its Phase 3 trials.
• The EASI-90 response rate of 47.4% for zumilokibart is strong, with Dupixent showing rates around 31.8% in its Phase 3 trials.
• The I-NRS4 response rate of 50.5% for zumilokibart indicates significant itch relief, comparable to or exceeding rates seen with other treatments.
• The EASI-100 (completely clear skin) response of 16.5% and Very Low Disease Activity (vLDA) response of 20.6% for zumilokibart are notable, suggesting potential for deeper disease control.
• The company highlights that zumilokibart's potential for dosing every 3-6 months in maintenance is a significant differentiator compared to more frequent dosing regimens of current standards of care like Dupixent (every 2 weeks).

Stakeholder Impact

• Shareholders: Positive clinical data and financing are expected to enhance shareholder value.
• Patients: Potential for a new, effective treatment option with improved dosing convenience for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis.
• Healthcare Providers: The data suggests a potentially best-in-class therapy that could become a new standard of care, offering robust efficacy and reduced treatment burden.

Next Steps

• Initiate Phase 3 trials of zumilokibart for moderate-to-severe atopic dermatitis (ADventure 1 and ADventure 2 monotherapy trials) in the second half of 2026.
• Initiate Phase 3 trial of zumilokibart in combination with topical corticosteroids (ADventure TCS) in the second half of 2026.
• Initiate Phase 2b ASPIRE trial for asthma in the first half of 2027.
• Initiate Phase 2a ELEVATE trial for eosinophilic esophagitis (EoE) in the second half of 2026.
• Announce further clinical plans for APG273 (zumilokibart+APG333) in the second half of 2026.
• Announce an additional pipeline program in the first half of 2027.
• Report Phase 2 APEX Part B 52-week maintenance data in the first half of 2027.
• Report Phase 2 APEX Part A 2-year follow-up data in the second half of 2027.

Key Dates

Recommendation

The strong positive clinical data, clear path to Phase 3 trials, expansion into multiple indications, and significant non-dilutive financing from Blackstone position Apogee Therapeutics for substantial future growth. The potential for zumilokibart to be a best-in-class therapy with a differentiated dosing profile makes it a highly attractive investment.

Keywords

Atopic Dermatitis, Zumilokibart, APG777, Phase 2 Trial, Clinical Results, Biotechnology, Inflammatory Diseases, Eczema